Matinas BioPharma Holdings Inc

For the period ended Dec 31, 2023. Filed Mar 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 27, 2024

MTNB$1.24+4.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Bedminster, State of New Jersey on March 27, 2024.

MATINAS BIOPHARMA HOLDINGS, INC.
By:	/s/ Jerome D. Jabbour
Name:	Jerome D. Jabbour
Title:	Chief Executive Officer
By:	/s/ Keith A. Kucinski
Name:	Keith A. Kucinski
Title:	Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Eric Ende
Person	Capacity	Date
/s/ Jerome D. Jabbour	Chief Executive Officer and Director	March 27, 2024
Jerome D. Jabbour	(Principal Executive Officer)
/s/ Keith A. Kucinski	Chief Financial Officer	March 27, 2024
Keith A. Kucinski	(Principal Financial and Accounting Officer)
/s/ Eric Ende	Chairman of the Board	March 27, 2024
/s/ Herbert Conrad	Director	March 27, 2024
Herbert Conrad
/s/ Kathryn Corzo	Director	March 27, 2024
Kathryn Corzo
/s/ Natasha Giordano	Director	March 27, 2024
Natasha Giordano
/s/ James S. Scibetta	Director	March 27, 2024
James S. Scibetta
/s/ Matthew A. Wikler	Director	March 27, 2024
Matthew A. Wikler

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.